Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2-Results of the induction phase of the GERCOR DREAM randomized phase III study.

Affiliation auteurs!!!! Error affiliation !!!!
TitreImproving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2-Results of the induction phase of the GERCOR DREAM randomized phase III study.
Type de publicationJournal Article
Year of Publication2015
AuteursTournigand C, Chibaudel B, Samson B, Scheithauer W, Lledo G, Artru P, Viret F, Ramee J-F, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Bonnetain F, Louvet C, Larsen AK, Andre T, de Gramont A, GERCOR, Multidisciplinaire GCooperateu
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume33
Date PublishedJAN 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2015.33.3_suppl.670